Categories
Change Password!
Reset Password!
Elagolix
could be consider a choice of treatment for endometriosis as it is
well-tolerated and does not cause loss of bone density like other GnRH
antagonists.
There
has been an extensive search for developing medications which can be used to
alleviate endometriosis-associated symptoms. Also, an already established
medication, a new GnRH antagonist, elagolix, is in development. Its nonpeptide
structure, allows it to be administered orally, which is its novelty to
compared to other GnRH antagonists.
Many Phase I, II and III clinical trials were analyzed, through which the
safety and efficacy of this new medication were evaluated.
According to the opinion of the researcher, as several medications have been
put on the market, which gained popularity for the alleviation of
endometriosis-associated symptoms. Elagolix has an advantage over established
GnRH agonists, in that it does not lead to a ‘flare-up’ effect, it too, takes a
toll on bone mineral density. However, studies have shown that this new oral
GnRH antagonist is well tolerated, and have ‘mild or moderate’ the side
effects. But there is a need for further studies in order to examine whether
elagolix can compete with or even surpass established gold-standard medical
treatments in this field, that directly compare elagolix to said treatments.
Expert Opin Pharmacother. 2017 Jul 24
Efficacy of elagolix in the treatment of endometriosis
Perricos A, Wenzl R
Comments (0)